Association of Bone Turnover Markers and Cognitive Function in Chinese Chronic Schizophrenia Patients with or Without Vitamin D Insufficiency

Overview

Journal BMC Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2023 Nov 22

PMID 37993797

Authors

Chen Ling

Liling Sun

Bei Luo

Haiyun Yu

Wei Li

Yating Yang

Huanzhong Liu

Affiliations

Soon will be listed here.

Abstract

Background: Increasing evidence shows that bone turnover markers (BTMs) and vitamin D can affect human cognitive function. However, there are few studies that have investigated the association between BTMs and cognitive function in chronic schizophrenia patients. The aim of this study was to investigate the relationship between BTMs and cognitive function in chronic schizophrenia patients with or without vitamin D insufficiency (VDI).

Methods: In all, 118 chronic schizophrenia patients were enrolled in this cross-sectional study. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was applied to evaluate the cognitive function of the subjects. Blood analysis included bone turnover markers, vitamin D levels, and glycolipid levels.

Results: Relative to 72 vitamin D-sufficient (VDS) patients, 46 VDI patients had higher bone resorption markers levels and lower bone formation markers levels. Regression analysis showed that, in the total sample, CTX and language function exhibited independent positive correlation (p = 0.027, R change = 0.042), and in the VDS group, procollagen type I N-terminal propeptide (PINP) was independently negatively correlated with language function (p = 0.031, R change = 0.065), while the positive correlation between osteopontin (OPN) and delayed memory remained in the VDI group (p = 0.036, R change = 0.083).

Conclusion: Our study showed an association between the levels of BTMs and cognitive function among chronic schizophrenia patients. This correlation may have different mechanisms of action at different vitamin D levels.

References

Oury F, Khrimian L, Denny C, Gardin A, Chamouni A, Goeden N . Maternal and offspring pools of osteocalcin influence brain development and functions. Cell. 2013; 155(1):228-41. PMC: 3864001. DOI: 10.1016/j.cell.2013.08.042. View

Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J . Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019; 6(3):211-224. DOI: 10.1016/S2215-0366(18)30511-X. View

Kovacs M, Tenyi T, Kugyelka R, Prenek L, Hau L, Magyar E . Elevated Osteopontin and Interferon Gamma Serum Levels and Increased Neutrophil-to-Lymphocyte Ratio Are Associated With the Severity of Symptoms in Schizophrenia. Front Psychiatry. 2020; 10:996. PMC: 6989480. DOI: 10.3389/fpsyt.2019.00996. View

Holick M, Binkley N, Bischoff-Ferrari H, Gordon C, Hanley D, Heaney R . Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(7):1911-30. DOI: 10.1210/jc.2011-0385. View

Otto E, Knapstein P, Jahn D, Appelt J, Frosch K, Tsitsilonis S . Crosstalk of Brain and Bone-Clinical Observations and Their Molecular Bases. Int J Mol Sci. 2020; 21(14). PMC: 7404044. DOI: 10.3390/ijms21144946. View

Qiu Y, Shen X, Ravid O, Atrakchi D, Rand D, Wight A . Definition of the contribution of an Osteopontin-producing CD11c microglial subset to Alzheimer's disease. Proc Natl Acad Sci U S A. 2023; 120(6):e2218915120. PMC: 9963365. DOI: 10.1073/pnas.2218915120. View

Mantere O, Trontti K, Garcia-Gonzalez J, Balcells I, Saarnio S, Mantyla T . Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis. J Psychiatr Res. 2018; 109:18-26. DOI: 10.1016/j.jpsychires.2018.11.008. View

Randolph C, Tierney M, Mohr E, Chase T . The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998; 20(3):310-9. DOI: 10.1076/jcen.20.3.310.823. View

Zhu J, Feng C, Zhang W, Wang Z, Zhong M, Tang W . Activation of dopamine receptor D1 promotes osteogenic differentiation and reduces glucocorticoid-induced bone loss by upregulating the ERK1/2 signaling pathway. Mol Med. 2022; 28(1):23. PMC: 8862482. DOI: 10.1186/s10020-022-00453-0. View

10.

Van Rheenen T, Ringin E, Karantonis J, Furlong L, Bozaoglu K, Rossell S . A preliminary investigation of the clinical and cognitive correlates of circulating vitamin D in bipolar disorder. Psychiatry Res. 2022; 320:115013. DOI: 10.1016/j.psychres.2022.115013. View

11.

Shea M, Barger K, Dawson-Hughes B, Leurgans S, Fu X, James B . Brain vitamin D forms, cognitive decline, and neuropathology in community-dwelling older adults. Alzheimers Dement. 2022; 19(6):2389-2396. PMC: 10244481. DOI: 10.1002/alz.12836. View

12.

Pettersen J . Does high dose vitamin D supplementation enhance cognition?: A randomized trial in healthy adults. Exp Gerontol. 2017; 90:90-97. DOI: 10.1016/j.exger.2017.01.019. View

13.

Puig J, Blasco G, Daunis-i-Estadella J, Moreno M, Molina X, Alberich-Bayarri A . Lower serum osteocalcin concentrations are associated with brain microstructural changes and worse cognitive performance. Clin Endocrinol (Oxf). 2015; 84(5):756-63. DOI: 10.1111/cen.12954. View

14.

Owusu J, Islam S, Katumuluwa S, Stolberg A, Usera G, Anwarullah A . Cognition and Vitamin D in Older African-American Women- Physical performance and Osteoporosis prevention with vitamin D in older African Americans Trial and Dementia. J Am Geriatr Soc. 2018; 67(1):81-86. DOI: 10.1111/jgs.15607. View

15.

Nerhus M, Berg A, Simonsen C, Haram M, Haatveit B, Dahl S . Vitamin D Deficiency Associated With Cognitive Functioning in Psychotic Disorders. J Clin Psychiatry. 2017; 78(7):e750-e757. DOI: 10.4088/JCP.16m10880. View

16.

Annweiler C, Schott A, Berrut G, Chauvire V, Le Gall D, Inzitari M . Vitamin D and ageing: neurological issues. Neuropsychobiology. 2010; 62(3):139-50. DOI: 10.1159/000318570. View

17.

Zhang B, Deng L, Wu H, Lu X, Peng L, Wu R . Relationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and β-CrossLaps. Schizophr Res. 2016; 176(2-3):259-263. DOI: 10.1016/j.schres.2016.06.034. View

18.

Cheng Y, Wu W, Wang J, Feng W, Wu X, Li C . Reliability and validity of the Repeatable Battery for the Assessment of Neuropsychological Status in community-dwelling elderly. Arch Med Sci. 2012; 7(5):850-7. PMC: 3258798. DOI: 10.5114/aoms.2011.25561. View

19.

Eastell R, Szulc P . Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017; 5(11):908-923. DOI: 10.1016/S2213-8587(17)30184-5. View

20.

Fleischhacker W, Arango C, Arteel P, Barnes T, Carpenter W, Duckworth K . Schizophrenia--time to commit to policy change. Schizophr Bull. 2014; 40 Suppl 3:S165-94. PMC: 4002061. DOI: 10.1093/schbul/sbu006. View